PT-141 (Bremelanotide) Satisfaction Trends Over Time: What Real-World Reviews Actually Show
HealthRX.com
Desire gains were small, and reviews vary widely
Key numbers
- 0.5 vs 0.2 pointsMean desire gain on the FSFI desire domain vs placebo in the 24-week bremelanotide trialsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 21%Share of patients reporting nausea after the first bremelanotide doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 18%Share of bremelanotide-treated patients who stopped because of adverse reactions, versus 2% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- Approved product / Vyleesi, FDA-approved June 21, 2019 [1][3]
- Approved population / Premenopausal women with acquired, generalized HSDD [1]
- Label dose / 1.75 mg subcutaneous, at least 45 minutes before activity; no more than one dose per 24 hours, and more than 8 doses a month is not recommended [1]
- Desire change at 24 weeks / 0.5 vs 0.2 and 0.6 vs 0.2 points, FSFI desire domain [1]
- Satisfying sexual events / No significant difference from placebo [2]
- Stopped for side effects / 18% on bremelanotide vs 2% on placebo [1]
- Nausea by dose / 21% after the first dose, about 3% after later doses [1]
- Duration of a dose / Unknown, per the label [1]
What the 24-week trials measured
Two identical phase 3 trials randomized 1,267 premenopausal women with acquired, generalized HSDD to bremelanotide 1.75 mg as needed or placebo for 24 weeks; 1,247 women made up the safety population and 1,202 the efficacy analysis, with a mean age of 39 [2]. The coprimary endpoints were the FSFI desire domain score and item 13 of the FSDS-DAO, a measure of distress about low desire [1][2]. Bremelanotide is a melanocortin receptor agonist, and how it improves HSDD is not known [1].
Desire improved more on bremelanotide than on placebo: a mean change from baseline of 0.5 vs 0.2 points in study 1 and 0.6 vs 0.2 in study 2 [1]. The published analysis reported the integrated desire difference versus placebo as 0.35 points, with separate values of 0.30 and 0.42 in the two studies (P<0.001 for each) [2]. The FSFI desire domain runs from 1.2 to 6.0, so these are small average shifts [1].
Desire-related distress moved the same way: FSDS-DAO item 13 fell by 0.37, 0.29 and 0.33 points more than on placebo in study 1, study 2 and the integrated analysis [2]. The label's tables give p-values of 0.0002 in study 1 and less than 0.0001 in study 2 for the desire domain [1].
On the question of satisfaction, the trials found no significant difference between bremelanotide and placebo in the number of satisfying sexual events [2].
Most patients in the phase 3 program used the drug two to three times a month and no more than once a week, and the median was 10 injections during the 24-week double-blind phase [1].
What people on Reddit report
Reddit accounts of bremelanotide use, mostly self-dosed. People report mixed results that vary by person, dose and timing, with some noting changes over repeated use.
- it takes time to dial in the dose and work out ones individual protocol.Read the source discussion
Injectables may stop working or results not as good as previous uses, but I believe this may need to be cycled.Read the source discussion
I unfortunately didn't feel any increase in the wanting sex part, but my body was more receptive.Read the source discussion
Questions worth asking
Nausea was most common after the first dose
Nausea was reported by 40.0% of women on bremelanotide versus 1.3% on placebo [1]. It required anti-nausea medicine in 13% and led 8% to stop the trials [1]. Incidence was highest after the first dose at 21% of patients, then fell to about 3% with later doses, and the label states that nausea improves for most patients with the second dose [1]. Median onset was within one hour of the injection and it lasted about two hours [1].
Oral ondansetron taken before Vyleesi did not reduce nausea in a phase 4 single-dose study of 228 healthy women, who were randomized to 8 mg oral ondansetron or placebo 30 minutes before a 1.75 mg subcutaneous dose; the label says this pre-treatment is not recommended [1]. Ondansetron given after the dose, or after nausea starts, has not been formally studied [1].
Other reactions in the pooled phase 3 table, bremelanotide vs placebo: flushing 20.3% vs 0.3%, injection site reactions 13.2% vs 8.4%, headache 11.3% vs 1.9%, vomiting 4.8% vs 0.2% [1]. Most events were mild (31%) or moderate (40%) and transient [1].
How many people stay on it
Discontinuation because of adverse reactions was 18% on bremelanotide versus 2% on placebo, led by nausea (8%), headache (2%), vomiting (1%), flushing (1%) and injection site reactions (1%) [1]. Total dropout across the 24-week double-blind phase was 40% vs 13% in study 1 and 39% vs 25% in study 2 [1]. Because more women stopped bremelanotide early, the label also reports an exploratory analysis limited to those who completed 24 weeks and improved from baseline [1].
The 52-week open-label extension gives a longer view, with caveats. Of 856 women who finished the core phase, 684 enrolled and 272 completed the extension, and all analyses were descriptive with no placebo arm [4]. The most common drug-related events in the extension were nausea 40.4%, flushing 20.6% and headache 12.0%, and the only severe treatment-emergent event experienced by more than one participant in both studies was nausea [4].
What shows up with longer or more frequent use
- Focal hyperpigmentation, meaning darkening of skin, gums or breasts, including the face, was reported by 1% of patients given up to 8 doses a month in the placebo-controlled trials, versus none on placebo [1]. In a separate study, 38% of patients developed it after daily dosing for 8 days, and a further 14% after 8 more consecutive days [1]. Risk is higher in darker skin and with daily dosing, and resolution was not confirmed in all patients after the drug was stopped [1]. The label says to consider discontinuing Vyleesi if hyperpigmentation develops [1].
- Blood pressure rises briefly after each dose. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute, usually back to baseline within 12 hours [1]. In an open-label ambulatory study of 127 premenopausal women dosed daily for 8 days, the mean daytime increase was 1.9 mmHg systolic and 1.7 mmHg diastolic, with a mean heart rate decrease of 0.5 beats per minute [1]. No additive effect was seen with daily dosing 24 hours apart for up to 16 days [1].
- The label contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease and does not recommend it in patients at high risk of cardiovascular disease [1].
- One case of acute hepatitis, with liver enzymes above 40 times normal, occurred after 10 doses in the open-label extension; no other cause was found, so a role for the drug could not be excluded [1].
Vyleesi and compounded PT-141 are not the same product
PT-141 reviews may describe different products. Bremelanotide is FDA-approved as Vyleesi, a 1.75 mg prefilled autoinjector, for premenopausal women with acquired, generalized HSDD: low desire causing marked distress that is not due to another medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for postmenopausal women or for men, and not to enhance sexual performance [1]. Approval came on June 21, 2019 under NDA 210557, and the current label holder is Cosette Pharmaceuticals [1][3].
PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug; compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are marketed [5][6]. Bremelanotide does not appear on the FDA's list of bulk drug substances that may present significant safety risks when compounded, and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [7][8].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Does satisfaction with PT-141 improve the longer you use it?
How many people stop bremelanotide because of side effects?
Does bremelanotide increase satisfying sexual events?
How long does a dose of PT-141 last?
Is PT-141 the same as Vyleesi?
What is the main longer-term skin effect listed on the label?
References
Show all 11 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- U.S. Food and Drug Administration.
- Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917.
- Official web page.
- Compounding and the FDA: Questions and Answers | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- Reddit participants. The libido peptide explained: what PT-141 actually does for sexual desire (r/NTNPerformance). Accessed 2026-11-11.
- Reddit participants. PT-141 Experience - it absolutely works (r/erectiledysfunction). Accessed 2026-11-11.
- Reddit participants. PT-141 (bremelanotide): the sexual health peptide that isn't a Viagra clone (r/NTNPerformance). Accessed 2026-11-11.